| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Dipeptidyl peptidase 2 |
|---|
| Ligand | BDBM514521 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | In Vitro Inhibition Assay |
|---|
| IC50 | 68000±n/a nM |
|---|
| Citation |  Bachovchin, WW; Lai, H; Wu, W Combination therapies using immuno-dash inhibitors and PGE2 antagonists US Patent US11096924 Publication Date 8/24/2021 |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Dipeptidyl peptidase 2 |
|---|
| Name: | Dipeptidyl peptidase 2 |
|---|
| Synonyms: | DAP II | DPP2 | DPP2_HUMAN | DPP7 | Dipeptidyl aminopeptidase II | Dipeptidyl peptidase 2 (DPP II) | Dipeptidyl peptidase 2 (DPP2) | Dipeptidyl peptidase II (DDP-II) | Dipeptidyl peptidase II (DPP II) | Dipeptidyl peptidase II (DPP2) | Dipeptidyl peptidase II and dipeptidyl peptidase IV (DPP2 and DPP4) | QPP | carboxytripeptidase | dipeptidyl arylamidase II | dipeptidyl(amino)peptidase II | dipeptidylarylamidase |
|---|
| Type: | Protein |
|---|
| Mol. Mass.: | 54339.29 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Q9UHL4 |
|---|
| Residue: | 492 |
|---|
| Sequence: | MGSAPWAPVLLLALGLRGLQAGARRAPDPGFQERFFQQRLDHFNFERFGNKTFPQRFLVS
DRFWVRGEGPIFFYTGNEGDVWAFANNSAFVAELAAERGALLVFAEHRYYGKSLPFGAQS
TQRGHTELLTVEQALADFAELLRALRRDLGAQDAPAIAFGGSYGGMLSAYLRMKYPHLVA
GALAASAPVLAVAGLGDSNQFFRDVTADFEGQSPKCTQGVREAFRQIKDLFLQGAYDTVR
WEFGTCQPLSDEKDLTQLFMFARNAFTVLAMMDYPYPTDFLGPLPANPVKVGCDRLLSEA
QRITGLRALAGLVYNASGSEHCYDIYRLYHSCADPTGCGTGPDARAWDYQACTEINLTFA
SNNVTDMFPDLPFTDELRQRYCLDTWGVWPRPDWLLTSFWGGDLRAASNIIFSNGNLDPW
AGGGIRRNLSASVIAVTIQGGAHHLDLRASHPEDPASVVEARKLEATIIGEWVKAARREQ
QPALRGGPRLSL
|
|
|
|---|
| BDBM514521 |
|---|
| n/a |
|---|
| Name | BDBM514521 |
|---|
| Synonyms: | US11096924, DASH-inhibitors 4268 | US11583516, Cmpd ID 4268 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C9H18BFN2O3 |
|---|
| Mol. Mass. | 232.06 |
|---|
| SMILES | CC(C)(F)[C@H](N)C(=O)N1CCC[C@H]1B(O)O |r| |
|---|
| Structure | 
|
|---|
Search and Browse
